Tatiana N Buhtoiarova 1 , Carol A Brenner 2 , Meenakshi Singh 3 Show Affiliations »
Abstract
OBJECTIVES: Type II and other high-grade endometrial carcinomas may challenge conventional treatment due to recurrence and metastatic spread and therefore are a persistent clinical dilemma. Effective targeted therapy for these is a goal for clinicians and researchers alike. METHODS: An extensive review of the literature has been performed for obtaining an in-depth understanding of the clinicopathological characteristics, etiologic factors, and molecular profile of these subsets of endometrial carcinoma. Progress made with current and emerging biomarkers for prognosis assessment and therapeutic targeting has been summarized. RESULTS: There has been a significant increase in research on potential biomarkers of endometrial cancer, and beneficial targeted therapies have been identified. CONCLUSIONS: Clinical trials are leading the charge for substantial gains toward personalized treatment of aggressive endometrial carcinoma subtypes. © American Society for Clinical Pathology, 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
OBJECTIVES: Type II and other high-grade endometrial carcinomas may challenge conventional treatment due to recurrence and metastatic spread and therefore are a persistent clinical dilemma. Effective targeted therapy for these is a goal for clinicians and researchers alike. METHODS: An extensive review of the literature has been performed for obtaining an in-depth understanding of the clinicopathological characteristics, etiologic factors, and molecular profile of these subsets of endometrial carcinoma . Progress made with current and emerging biomarkers for prognosis assessment and therapeutic targeting has been summarized. RESULTS: There has been a significant increase in research on potential biomarkers of endometrial cancer , and beneficial targeted therapies have been identified. CONCLUSIONS: Clinical trials are leading the charge for substantial gains toward personalized treatment of aggressive endometrial carcinoma subtypes . © American Society for Clinical Pathology, 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Entities: Disease
Keywords:
Biomarkers; Endometrial carcinoma; Targeted therapy
Mesh： See more »
Substances： See more »
Year: 2016
PMID： 26712866 DOI： 10.1093/ajcp/aqv014
Source DB: PubMed Journal: Am J Clin Pathol ISSN： 0002-9173 Impact factor: 2.493